APA (7th ed.) Citation

Abdelaziz, L. A., Taha, H. F., Ali, M. M., Abdelgawad, M. I., & Elwan, A. (2021). Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: A prospective randomized multi-centric Egyptian study. Termedia Publishing House.

Chicago Style (17th ed.) Citation

Abdelaziz, Lobna A., Heba F. Taha, Magid M. Ali, Marwa I. Abdelgawad, and Amira Elwan. Tolerability and Outcome of Sunitinib by Giving 4/2 Schedule Versus 2/1 schedule in Metastatic Renal Cell Carcinoma Patients: A Prospective Randomized Multi-centric Egyptian Study. Termedia Publishing House, 2021.

MLA (8th ed.) Citation

Abdelaziz, Lobna A., et al. Tolerability and Outcome of Sunitinib by Giving 4/2 Schedule Versus 2/1 schedule in Metastatic Renal Cell Carcinoma Patients: A Prospective Randomized Multi-centric Egyptian Study. Termedia Publishing House, 2021.